Process Analytical Technology-Based In-Line Buffer Dilution In Downstream Bioprocessing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Process Analytical Technology-Based In-Line Buffer Dilution In Downstream Bioprocessing
The authors describe the operational requirements and design of a process-ready PAT-based IBD system.


Pharmaceutical Technology
Volume 34, pp. s18-s22

PAT-based in-line buffer dilution


Figure 2: A process analytical technology-based in-line buffer-dilution skid equipped with conductivity and pH process analyzers linked with a process feedback-control loop.
This article examines the operational requirements and design of a process-ready PAT-based in-line buffer-dilution (IBD) system, which is capable of making reproducible and accurate in-line buffer dilutions in concentrations as high as 100 of the product using conductivity or pH feedback control. The technology can be used within stand-alone packaged equipment or engineered into a process-scale liquid chromatography skid. In the latter option, mobile phases are made on demand and sent directly to a process column for a sequence of chromatography steps in a purification regime. The comparison of a PAT-based and a mass-flow control system includes conductivity gradients, which are typical for biochromatographic processes, and the generation of linear pH gradients with good acidity control.


Figure 3: Piping and instrumentation diagram screen of a process analytical technology-based in-line buffer-dilution system.
The literature includes several examples of diluting buffers from concentrates in processes consistent with QbD (3). Some biopharmaceutical companies currently use a patented PAT-based IBD skid for buffer preparation and dilution (see Figure 2). To understand how IBD assists the QbD paradigm recommended by FDA, one should examine the basic technology platform. Figure 3 shows a sample piping and instrumentation diagram (P&ID) from the process-control screen of an IBD system.

A typical PAT-based IBD skid consists of three pumps labeled P001, P002, and P102. Deionized water for injection (WFI) is connected to P001, and buffer at concentrations as high as 100 of the product is connected to P002. WFI and buffer concentrate are pumped into a blending loop, where the buffer concentrate is diluted to 1 the product. The diluted buffer has a specific conductivity that can be analyzed by an in-line process conductivity sensor linked to a process-control feedback loop. The sensor continuously analyzes the conductivity of the buffer blend in the loop and sends an output signal to the process-control feedback loop. The loop then compares the current process conductivity value with a user-defined conductivity target set point for the buffer diluted to 1 the product. Based on the feedback signal, the concentrate pump speeds can be increased or decreased. Whenever the acidity of the buffer solution must be adjusted, alkali or acid can be delivered from P102. In this instance, a pH probe would be installed in the blending loop and linked with its own process-control feedback loop to adjust the solution's pH to meet the user's specifications.

To assess the ability of a PAT-based IBD system to monitor a process and to actively manipulate it to maintain a desired state, the authors performed experiments to compare simple mass-flow and PAT-based control blending, and to reveal the true benefits of directly measuring the quantity of raw materials present during runs. The first experiment was a buffer-preparation scenario in which errors in the formulation of the concentrate raw material can cause an out-of-specification buffer-dilution product. The second comparison was made in the context of producing a linear pH gradient with pH adjustment and control not commonly available in a mass-flow-based dilution system.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here